New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
10:21 EDTFIO, MTOR, VRTX, APOL, SBGI, OHRP, IRM, UNXL, ACHNOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ACHN SBGI MTOR UNXL APOL FIO IRM CBS
News For OHRP;VRTX;ACHN;SBGI;MTOR;UNXL;APOL;FIO;IRM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
February 3, 2016
08:02 EDTMTORMeritor reports Q1 adjusted EPS 33c, consensus 37c
Reports Q1 revenue $809M, consensus $845.94M. The decrease in sales was driven by the effect of foreign exchange translation in Europe and Brazil and weak economic conditions in South America.
February 1, 2016
14:23 EDTIRMIron Mountain backs FY16 revenue view $3.165B-$3.265B, consensus $3.1B
Guidance provided in slides presentation.
10:00 EDTVRTXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Air Products (APD) upgraded to Buy from Neutral at UBS... American Airlines (AAL) upgraded to Outperform from Market Perform at Cowen... Axiall (AXLL) upgraded to Overweight from Neutral at JPMorgan... BASF (BASFY) upgraded to Buy from Hold at Societe Generale... CNH Industrial (CNHI) upgraded to Neutral from Underperform at BofA/Merrill... CU Bancorp (CUNB) upgraded to Outperform from Market Perform at Fig Partners... CaixaBank (CAIXY) upgraded to Hold from Sell at Societe Generale... Chipotle (CMG) upgraded to Neutral from Underperform at BofA/Merrill... Concho Resources (CXO) upgraded to Buy from Neutral at SunTrust... Continental Building (CBPX) upgraded to Buy from Hold at BB&T... Eastman Chemical (EMN) upgraded to Buy from Outperform at CLSA... Extreme Networks (EXTR) upgraded to Buy from Hold at Needham... Glacier Bancorp (GBCI) upgraded to Outperform from Market Perform at Fig Partners... IBERIABANK (IBKC) upgraded to Strong Buy from Outperform at Raymond James... Infineon (IFNNY) upgraded to Buy from Neutral at UBS... Jarden (JAH) upgraded to Outperform from Market Perform at Raymond James... Joy Global (JOY) upgraded to Overweight from Equal Weight at Barclays... KT Corporation (KT) upgraded to Overweight from Neutral at JPMorgan... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... L-3 Communications (LLL) upgraded to Buy on valuation at BofA/Merrill... Maximus (MMS) upgraded to Outperform from Market Perform at Raymond James... Micron (MU) upgraded to Neutral from Sell at Goldman... Monster Beverage (MNST) upgraded to Outperform from Market Perform at Wells Fargo... Newell Rubbermaid (NWL) upgraded to Outperform from Market Perform at Raymond James... Northrop Grumman (NOC) upgraded to Buy from Neutral at BofA/Merrill... PTC (PTC) upgraded to Buy from Neutral at Sterne Agee CRT... Peoples Bancorp (PEBO) upgraded to Outperform from Neutral at Boenning & Scattergood... Praxair (PX) upgraded to Buy from Neutral at UBS... Proofpoint (PFPT) upgraded to Outperform from In-Line at Imperial Capital... Seagate (STX) upgraded to Hold from Sell at Benchmark... Siemens (SIEGY) upgraded to Buy from Neutral at Nomura... Superior Drilling (SDPI) upgraded to Buy from Hold at Wunderlich... Vertex (VRTX) upgraded to Buy from Hold at Jefferies... Werner (WERN) upgraded to Strong Buy from Outperform at Raymond James... ZAIS Financial (ZFC) upgraded to Overweight from Equal Weight at Barclays.
06:09 EDTVRTXVertex upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Abrahams upgraded Vertex Pharmaceuticals to Buy saying current share levels provide a good long-term entry point. In the low $90s, the stock reflects an "excessively cautious" case on future label expansions for Orkambi, Abrahams tells investors in a research note. He continues to believe in Vertex's long-term cystic fibrosis sales opportunity. The analyst cut his price target for the shares to $120 from $142. The biotechnology company closed Friday down $2.01 to $90.75.
January 29, 2016
09:34 EDTACHNAchillion downgraded to Market Perform from Outperform at Leerink
Subscribe for More Information
08:49 EDTAPOLApollo Education investor pushes board to reconsider sale, Bloomberg says
Subscribe for More Information
January 28, 2016
07:45 EDTSBGISinclair Broadcast to hold a conference call
Subscribe for More Information
05:59 EDTVRTXVertex price target lowered to $143 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Vertex Pharmaceuticals to $143 to reflect reduced cystic fibrosis sales assumptions following the company's Q4 results. The analyst says there is "no surprises" in Vertex's quarter and keeps an Overweight rating on the name.
January 27, 2016
19:30 EDTVRTXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Facebook (FB), up 11.4%... Mellanox (MLNX), up 6.4%... Paypal (PYPL), up 5%... Crown Castle (CCI), up 2.2%... Citrix (CTXS), up 2.4%... Las Vegas Sands (LVS), up 1%... SanDisk (SNDK), up 1%. ALSO HIGHER: Radius Health (RDUS), up 1.2% after announcing a clinical collaboration with Novartis (NVS)... LinkedIn (LNKD) is up 2.4%, Alphabet (GOOG, GOOGL) is up 2.2% and 2.6%, respectively, Netflix (NFLX) is up 1%, Amazon.com (AMZN) is up 2%, and Twitter (TWTR) is up marginally after Facebook reported quarterly results... MGM Resorts (MGM) is up 2.2% and Wynn Resorts (WYNN) is up 2.2%. DOWN AFTER EARNINGS: ServiceNow (NOW), down 16.5%... eBay (EBAY), down 12.8%... United Rentals (URI), down 9.7%... Juniper Networks (JNPR), down 9.6%... Silicon Graphics (SGI), down 9.1%... Discover Financial (DFS), down 7.4%... InvenSense (INVN), down 6.1%... Core Laboratories (CLB), down 4.3%... Vertex Pharmaceuticals (VRTX), down 1.1%. ALSO LOWER: Incyte (INCY), down 12.8% after announcing that it will halt the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.
16:41 EDTSBGISinclair Broadcast to acquire Tennis Channel for $350M
Subscribe for More Information
16:05 EDTVRTXVertex backs FY16 net product revenue guidance for KALYDECO of $670M-$690M
Vertex expects to provide net product revenue guidance for ORKAMBI during 2016 after gaining additional information on the launch of ORKAMBI in the U.S.
16:04 EDTVRTXVertex reports Q4 EPS 17c, consensus 17c
Subscribe for More Information
14:34 EDTVRTXNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Facebook (FB), consensus 68c... Qualcomm (QCOM), consensus 90c... Texas Instruments (TXN), consensus 69c... McKesson (MCK), consensus $3.13... PayPal (PYPL), consensus 35c... Las Vegas Sands (LVS), consensus 65c... eBay (EBAY), consensus 50c... Crown Castle (CCI), consensus $1.10... Vertex (VRTX), consensus 17c... Discover (DFS), consensus $1.30... SanDisk (SNDK), consensus 89c... ServiceNow (NOW), consensus 8c... Lam Research (LRCX), consensus $1.43... Citrix Systems (CTXS), consensus $1.19... Hologic (HOLX), consensus 42c... Juniper (JNPR), consensus 59c... Cavium (CAVM), consensus 28c... Cirrus Logic (CRUS), consensus 81c.
12:28 EDTAPOLFor-profit education names fall after FTC sues DeVry over marketing
DeVry Education (DV) and its peers in the for-profit education space are falling after the Federal Trade Commission filed suit against the company, alleging that DeVry's advertisements "deceived" consumers about the likelihood of finding jobs in their chosen fields of study and earning more than graduates from other universities. In a related action, the Department of Education is also moving against the company for those same practices, requiring it to stop the allegedly deceptive advertisements and take steps to ensure it can verify the truthfulness of its post-graduation employment outcomes, including hiring an independent auditor and informing students of its "unsubstantiated" statistics. The Department's action comes after its investigation of DeVry found the postgraduation employment claims "have not been substantiated to the extent required by law." PRICE ACTION: Shares of DeVry crashed 13.5% to $20.54 following the news, while Apollo Education (APOL), ITT Educational (ESI) and Strayer Education (STRA) each slid over 2% and Bridgepoint (BPI) fell 1%.
12:07 EDTAPOLDeVry sinks 19% after FTC brings enforcement action
Peers Apollo Education (APOL), Strayer (STRA), Grand Canyon (LOPE) and Bridgepoint Education (BPI) are also moving lower.
11:27 EDTVRTXOptions with increasing call volume
Subscribe for More Information
10:04 EDTVRTXHigh option volume stocks: RDN TRXC EEFT CVLT VRTX
January 26, 2016
17:21 EDTVRTXVertex announces Health Canada approved PrORKAMBI
Subscribe for More Information
07:29 EDTVRTXChecks indicate worries over Vertex Orkambi overdone, says Stifel
After conducting checks with cystic fibrosis doctors, Stifel says the checks indicate that the Street's worries regarding Orkambi uptake, adherence, and persistence are overdone. The firm remains upbeat on the drug's longer term outlook and keeps a $160 price target and Buy rating on the shares.
06:55 EDTAPOLApollo could be worth $17/share if taken private, says Piper Jaffray
Piper Jaffray analyst Peter Appert says Apollo Education Group could be worth $13-$17 per share in a go-private transaction. The stock has "meaningful" upside potential if the company can overcome the legal, regulatory and financial hurdles to complete a sale transaction, Appert tells investors in a research note. He says there is "considerable uncertainty" as to whether Apollo can overcome such challenges. The analyst keeps a Neutral rating on the stock with a $9 price target.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use